Octreotide vs. Splenic Artery Ligation for Portal Flow Modulation in Living Donor Liver Transplants (SCALOP Trial)
- Conditions
- Small-for-Size Syndrome
- Interventions
- Procedure: Splenic Artery Ligation (SAL)
- Registration Number
- NCT06974344
- Brief Summary
The goal of this clinical trial is to compare two treatments for regulating blood flow in small liver grafts during living donor liver transplantation (LDLT). The main questions it aims to answer are:
* Is octreotide (a medication) as effective or better than splenic artery ligation (surgery) in reducing complications after transplantation?
* Which treatment better controls blood flow while causing fewer side effects?
Researchers will compare octreotide (given through an IV) to splenic artery ligation (performed during surgery) to see which approach works best for patients receiving small liver grafts.
Participants will:
* Be randomly assigned to receive either octreotide or splenic artery ligation during their transplant surgery
* Have their liver blood flow monitored closely during and after surgery
Be followed for 90 days and 1 year to track complications, hospital stay, recovery, and survival.
This study may help doctors choose safer, more effective treatments for patients needing small liver grafts.
- Detailed Description
This randomized controlled trial (SCALOP-RCT) investigates two strategies for managing portal hyperperfusion in adults receiving small living donor liver transplants (graft-to-recipient weight ratio \<0.80%). Small grafts are prone to injury from high venous portal and low hepatic artery flow, leading to small-for-size syndrome (SFSS), a major cause of transplant failure.
Interventions Compared
* Octreotide: A somatostatic analogue that reduces portal venous flow and increased hepatic artery flow to the liver by constricting blood vessels, given continuously through an IV during and after surgery.
* Splenic Artery Ligation (SAL): A surgical procedure that ties off the artery supplying the spleen, indirectly lowering portal venous flow.
Study Design
* Randomization: Participants are assigned 1:1 to octreotide or SAL during transplant surgery.
* Rescue Protocol: If portal venous flow remains too high after the initial treatment, patients may switch to the alternative therapy (crossover).
* Blinding: Surgeons know the treatment, but outcome assessors and data analysts do not.
Key Assessments
* Primary: Total complication burden at 90 days (Comprehensive Complication Index(R) (CCI(R)).
* Secondary: Blood flow measurements, early liver function, hospital stay, survival, and quality of life.
* Rationale: Current approaches vary widely, with no consensus on whether medications or surgery work better. This trial will provide evidence to standardize care, potentially improving graft survival and expanding donor options.
* Population: 80 adults (18-70 years) undergoing LDLT at a single tertiary center.
* Innovation: First head-to-head comparison of these strategies with rigorous hemodynamic monitoring and crossover rescue design.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 80
- Age ≥ 18 and <70 years
- Male and female genders
- Undergoing Living Donor Liver Transplant (LDLT)
- All indications
- Receiving a small-for-size graft requiring portal flow modulation
- Informed consent provided.
- Deceased Donor Liver Transplantation (DDLT)
- Dual LDLT or dual LDLT/DDLT
- Pregnancy
- Known allergy to Octreotide / Somatostatin analogue
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Octreotide Infusion Arm Octreotide (drug) Continuous intravenous octreotide (1 mcg/kg/hr) initiated at liver graft reperfusion and continued postoperatively until hemodynamic stability is achieved. Splenic Artery Ligation (SAL) Arm Splenic Artery Ligation (SAL) Intraoperative ligation of the splenic artery using non-absorbable suture near its origin.
- Primary Outcome Measures
Name Time Method Median Comprehensive Complication Index® (CCI®) From the day of liver transplantation (Day 0) through postoperative day 90. The Comprehensive Complication Index® (CCI®) is a validated, quantitative metric that reflects the cumulative burden of postoperative complications by integrating all complications experienced by a patient into a single continuous scale (range: 0 (no complications) to 100 (death)). The CCI® is calculated using the Clavien-Dindo Classification to grade the severity of each complication (Grades I-V), with weights assigned based on clinical impact.
Small-for-size syndrome (SFSS) rate From the day of liver transplantation (Day 0) through postoperative day 14 SFSS is a clinically defined syndrome occurring in recipients of small-for-size liver grafts (graft-to-recipient weight ratio (GRWR) \<0.80%), characterized by:
* Persistent cholestasis (serum total bilirubin \>5.8 mg/dL beyond postoperative day 14)
* Refractory ascites (daily ascitic fluid output \>1 L despite diuretics beyond day 14)
* Coagulopathy (INR \>2 with hypoalbuminemia \<2.5 g/dL beyond day 14)
Diagnostic Criteria
* Requires ≥2 of the above features (per ILTS-iLDLT-LTSI 2023 Consensus Guidelines).
* Excludes other causes of graft dysfunction (e.g., hepatic artery thrombosis, acute rejection).Number and proportion of postoperative complication types and grades within 90 days From the day of liver transplantation (Day 0) through postoperative day 90 All complications occurring within 90 days post-transplantation will be prospectively recorded and graded using the Clavien-Dindo Classification, a validated system for surgical morbidity.
* Grade I: Minor deviations (e.g., antipyretics for fever, bedside wound care).
* Grade II: Pharmacological treatment (e.g., antibiotics for infection).
* Grade III: Surgical/endoscopic intervention (IIIa: local anesthesia; IIIb: general anesthesia).
* Grade IV: Life-threatening (IVa: single-organ dysfunction; IVb: multi-organ failure).
* Grade V: Death.Adequate portal flow modulation response rate From intervention completion (T=0) to 60 minutes post-intervention The proportion of patients achieving target hemodynamic parameters following intervention (octreotide or splenic artery ligation), defined as:
* Portal venous flow (PVF) \<5 mL/min/graft weight and
* Presence of diastolic hepatic arterial flow on Doppler ultrasound post-intervention.Mortality rate From the day of liver transplantation (Day 0) through postoperative day 90 All-cause mortality occurring within 90 days post-transplantation, regardless of relationship to the intervention or underlying liver disease. This will the proportion of deaths over total number of patients within each arm and reported in percentage.
- Secondary Outcome Measures
Name Time Method Graft survival rate at 1-year post-transplantation From the day of liver transplantation (Day 0) through postoperative day 365 The proportion of patients with a functional liver graft (alive without retransplantation) at 1 year post-transplant, analyzed by including all graft losses (death or retransplantation) using the Kaplan-Meier test.
Patient survival rate at 1-year post-transplantation From the day of liver transplantation (Day 0) through postoperative day 365 The proportion of patients with alive at 1 year post-transplant, analyzed using the Kaplan-Meier test.
Median portal venous flow (PVF) rate on intraoperative Liver Doppler ultrasound Intraoperative (post-reperfusion) and postoperative (daily) timepoints until day 20 postoperatively or hospital discharge Portal venous flow (PVF): Volume flow rate (mL/min) normalized to graft weight (mL/min/g)
Median Hepatic artery resistive index (RI) on intraoperative Liver Doppler ultrasound Intraoperative (post-reperfusion) and postoperative (daily) timepoints until day 20 postoperatively or hospital discharge Hepatic artery resistive index (RI): (Peak systolic velocity - End diastolic velocity)
Hepatic artery diastolic flow rate Intraoperative (post-reperfusion) and postoperative (daily) timepoints until day 20 postoperatively or hospital discharge Binary presence or absence rate of end- diastolic flow on Liver Doppler Ultrasound
Median intensive care unit length of stay in days Days from admission to the Intensive Care Unit (ICU) (typically Day 0 to Day 4 postoperatively) until ICU discharge to the surgical ward. Total number of days in the Intensive care unit (ICU) during the primary admission, from the day of transplant (Day 0) until discharge to the surgical ward.
Median hospital length of stay in days From the day of liver transplantation (Day 0) until hospital discharge (typically day 20 postoperatively) Total number of days patient hospitalized during the index procedure
Quality of Life Assessment (36-Item Short Form Health Survey, SF-36) (median values) Measured at baseline (pre-transplant), 3 months, 6 months, and 12 months post-transplantation. The 36-Item Short Form Health Survey (SF-36) is a validated patient-reported outcome measure that assesses health-related quality of life. The SF-36 consists of eight subscales, which are further summarized into two component scores:
* Physical Component Summary (PCS): Includes physical functioning, role-physical, bodily pain, and general health.
* Mental Component Summary (MCS): Includes vitality, social functioning, role-emotional, and mental health.
Scoring: Each subscale is scored from 0 to 100, where higher scores indicate better health-related quality of life. The median scores will be compared between the two groups.
Trial Locations
- Locations (1)
Organ Transplant Center of Excellence, King Faisal Specialist Hospital and Research Center
🇸🇦Riyadh, Saudi Arabia